Inside Moderna’s Personalized Cancer Vaccine

Moderna’s recent Phase 3 clinical trial for an individualized mRNA melanoma vaccine marks a breakthrough in cancer treatment by demonstrating superior efficacy when combined with immunotherapy. Unlike traditional vaccines that use shared antigens, this approach sequences a patient’s tumor DNA against healthy cells to identify unique mutations. An algorithm then selects the most relevant targets to create a personalized mRNA molecule that trains the immune system to recognize and attack specific cancer cells. This method is orthogonal to checkpoint inhibitors like Keytruda, which release immune system brakes, allowing for a synergistic effect that improves recurrence-free survival. With 90% of antigens varying between patients, the platform relies on a highly automated, scalable manufacturing process. Future development aims to expand this technology to other solid tumors, rare genetic liver diseases, and potentially the root causes of autoimmune disorders.